| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
80,420,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Verve Therapeutics is a genetic medicines company developing an approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Co.'s primary product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver. PCSK9 is a validated target that plays a critical role in controlling blood low-density lipoprotein cholesterol through its regulation of the low-density lipoprotein receptor. Co.'s second program is designed to turn off the ANGPTL3 gene in the liver. ANGPTL3 is a main regulator of cholesterol and triglyceride metabolism.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,800,000 |
1,800,000 |
1,810,000 |
| Total Buy Value |
$0 |
$18,000,000 |
$18,000,000 |
$18,121,526 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
2 |
| Total Shares Sold |
1,514 |
2,068 |
2,068 |
1,570,794 |
| Total Sell Value |
$12,475 |
$18,818 |
$18,818 |
$35,262,071 |
| Total People Sold |
1 |
2 |
2 |
7 |
| Total Sell Transactions |
1 |
2 |
2 |
35 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nickerson Joan |
Chief Administrative Officer |
• – – |
2024-04-02 |
4 |
S |
$8.24 |
$12,475 |
D/D |
(1,514) |
8,659 |
|
- |
|
| Nickerson Joan |
Chief Administrative Officer |
• – – |
2024-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,315 |
10,173 |
|
- |
|
| Alphabet Inc. |
|
– – – |
2023-12-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,800,000 |
|
- |
|
| Yeshwant Krishna |
|
– • • |
2023-12-01 |
4 |
B |
$10.00 |
$18,000,000 |
I/I |
1,800,000 |
1,800,000 |
0.01 |
- |
|
| Dorval Allison |
Chief Financial Officer |
• – – |
2023-11-29 |
4 |
S |
$11.45 |
$6,343 |
D/D |
(554) |
4,060 |
|
- |
|
| Dorval Allison |
Chief Financial Officer |
• – – |
2023-11-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,875 |
4,614 |
|
- |
|
| Nickerson Joan |
Chief Administrative OfficerOf |
• – – |
2023-02-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,494 |
|
- |
|
| Bellinger Andrew |
CSO & CMO |
• – – |
2022-12-14 |
4 |
OE |
$2.87 |
$103,320 |
D/D |
36,000 |
42,629 |
|
- |
|
| Bellinger Andrew |
CSO & CMO |
• – – |
2022-12-01 |
4 |
S |
$22.95 |
$19,852 |
D/D |
(865) |
6,629 |
|
- |
|
| Dorval Allison |
Chief Financial Officer |
• – – |
2022-11-29 |
4 |
S |
$22.10 |
$12,243 |
D/D |
(554) |
2,186 |
|
- |
|
| Dorval Allison |
Chief Financial Officer |
• – – |
2022-11-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,875 |
2,740 |
|
- |
|
| Alphabet Inc. |
Member of 10% Group |
– – – |
2022-11-04 |
4 |
AS |
$31.12 |
$3,025,611 |
I/I |
(97,166) |
4,260,047 |
|
- |
|
| Alphabet Inc. |
Member of 10% Group |
– – – |
2022-11-04 |
4 |
AS |
$0.00 |
$0 |
I/I |
(48,583) |
6,108,442 |
|
- |
|
| Yeshwant Krishna |
Director |
– • • |
2022-11-04 |
4 |
AS |
$31.12 |
$1,512,806 |
I/I |
(48,583) |
4,260,047 |
|
- |
|
| Yeshwant Krishna |
Director |
– • • |
2022-11-04 |
4 |
AS |
$0.00 |
$0 |
I/I |
(48,583) |
6,108,442 |
|
- |
|
| Yeshwant Krishna |
Director |
– • • |
2022-11-03 |
4 |
AS |
$32.32 |
$1,625,497 |
I/I |
(49,568) |
4,308,630 |
|
- |
|
| Yeshwant Krishna |
Director |
– • • |
2022-11-03 |
4 |
AS |
$0.00 |
$0 |
I/I |
(49,569) |
6,157,025 |
|
- |
|
| Alphabet Inc. |
Member of 10% Group |
– – – |
2022-11-03 |
4 |
AS |
$32.32 |
$3,251,028 |
I/I |
(99,137) |
4,308,630 |
|
- |
|
| Alphabet Inc. |
Member of 10% Group |
– – – |
2022-11-03 |
4 |
AS |
$0.00 |
$0 |
I/I |
(49,569) |
6,157,025 |
|
- |
|
| Yeshwant Krishna |
Director |
– • • |
2022-11-02 |
4 |
AS |
$34.78 |
$1,029,832 |
I/I |
(28,652) |
4,358,198 |
|
- |
|
| Yeshwant Krishna |
Director |
– • • |
2022-11-02 |
4 |
AS |
$0.00 |
$0 |
I/I |
(28,651) |
6,206,594 |
|
- |
|
| Alphabet Inc. |
Member of 10% Group |
– – – |
2022-11-02 |
4 |
AS |
$34.78 |
$2,059,630 |
I/I |
(57,303) |
4,358,198 |
|
- |
|
| Alphabet Inc. |
Member of 10% Group |
– – – |
2022-11-02 |
4 |
AS |
$0.00 |
$0 |
I/I |
(28,651) |
6,206,594 |
|
- |
|
| Yeshwant Krishna |
Director |
– • • |
2022-11-01 |
4 |
AS |
$36.69 |
$1,175,853 |
I/I |
(31,963) |
4,386,850 |
|
- |
|
| Yeshwant Krishna |
Director |
– • • |
2022-11-01 |
4 |
AS |
$0.00 |
$0 |
I/I |
(31,963) |
6,235,245 |
|
- |
|
99 Records found
|
|
Page 1 of 4 |
|
|
